Biodexa Pharmaceticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatm… Read more
Biodexa Pharmaceticals (BDRX) - Total Assets
Latest total assets as of June 2025: $14.82 Million USD
Based on the latest financial reports, Biodexa Pharmaceticals (BDRX) holds total assets worth $14.82 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Biodexa Pharmaceticals - Total Assets Trend (2012–2024)
This chart illustrates how Biodexa Pharmaceticals’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Biodexa Pharmaceticals - Asset Composition Analysis
Current Asset Composition (December 2024)
Biodexa Pharmaceticals's total assets of $14.82 Million consist of 59.6% current assets and 40.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.3% |
| Accounts Receivable | $715.00K | 4.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $5.65 Million | 38.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Biodexa Pharmaceticals's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biodexa Pharmaceticals's current assets represent 59.6% of total assets in 2024, an increase from 49.4% in 2012.
- Cash Position: Cash and equivalents constituted 11.3% of total assets in 2024, up from 6.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 38.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 38.2% of total assets.
Biodexa Pharmaceticals Competitors by Total Assets
Key competitors of Biodexa Pharmaceticals based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Biodexa Pharmaceticals - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Biodexa Pharmaceticals generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Biodexa Pharmaceticals is currently not profitable relative to its asset base.
Biodexa Pharmaceticals - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.63 | 2.16 | 1.40 |
| Quick Ratio | 3.63 | 2.16 | 1.40 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.51 Million | $ 4.04 Million | $ 2.92 Million |
Biodexa Pharmaceticals - Advanced Valuation Insights
This section examines the relationship between Biodexa Pharmaceticals's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.05 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 40.2% |
| Total Assets | $14.78 Million |
| Market Capitalization | $796.76K USD |
Valuation Analysis
Below Book Valuation: The market values Biodexa Pharmaceticals's assets below their book value (0.05 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Biodexa Pharmaceticals's assets grew by 40.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Biodexa Pharmaceticals (2012–2024)
The table below shows the annual total assets of Biodexa Pharmaceticals from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $14.78 Million | +40.20% |
| 2023-12-31 | $10.54 Million | +90.81% |
| 2022-12-31 | $5.53 Million | -57.21% |
| 2021-12-31 | $12.91 Million | +31.54% |
| 2020-12-31 | $9.82 Million | -68.22% |
| 2019-12-31 | $30.89 Million | +51.12% |
| 2018-12-31 | $20.44 Million | -58.47% |
| 2017-12-31 | $49.22 Million | -13.17% |
| 2016-12-31 | $56.69 Million | -11.48% |
| 2015-12-31 | $64.04 Million | +37.24% |
| 2014-12-31 | $46.66 Million | +801.87% |
| 2013-12-31 | $5.17 Million | +132.96% |
| 2012-12-31 | $2.22 Million | -- |